Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hemangiosarcoma × avelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 25 Carcinoma, Transitional Cell 22 Urinary Bladder Neoplasms 21 Neoplasms 20 Carcinoma, Merkel Cell 18 Neoplasm Metastasis 17 Carcinoma, Renal Cell 15 Breast Neoplasms 15 Colorectal Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 12 Ovarian Neoplasms 12 Triple Negative Breast Neoplasms 8 Head and Neck Neoplasms 8 Pancreatic Neoplasms 7 Stomach Neoplasms 6 Melanoma 6 Recurrence 5 Prostatic Neoplasms 5 Carcinoma, Hepatocellular 5 Ureteral Neoplasms 4 Small Cell Lung Carcinoma 4 Neuroendocrine Tumors 4 Carcinoma, Squamous Cell 4 Uterine Cervical Neoplasms 3 Urethral Neoplasms 3 Skin Neoplasms 3 Sarcoma 3 Lymphoma 3 Leukemia, Myeloid, Acute 3 Kidney Neoplasms 3

Interventions

Doxorubicin 15 Ifosfamide 9 pazopanib 6 Paclitaxel 6 pembrolizumab 4 Radiotherapy 4 Gemcitabine 4 Filgrastim 4 spartalizumab 3 durvalumab 3 Sorafenib 3 Propranolol 3 Nivolumab 3 Ipilimumab 3 Docetaxel 3 trebananib 2 cixutumumab 2 carotuximab 2 brostallicin 2 belinostat 2 balstilimab 2 Trabectedin 2 Sunitinib 2 Standard of Care 2 Radiotherapy, Conformal 2 Magnetic Resonance Spectroscopy 2 Imatinib Mesylate 2 Epirubicin 2 Carboplatin 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03512834 2018-07-11

ASAP

Dong-A University Hospital

Phase 2 Unknown

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡